Articles
Good CME practice

Good CME practice

Dr Edwin Borman shares his criteria for good CME practice. What constitutes good CME practice? We asked Dr Edwin Borman, consultant anaesthetist and secretary general of...

Articles
What does AstraZeneca look for in a licensing partner?

What does AstraZeneca look for in a licensing partner?

What does AstraZeneca look for in a licensing partner? We asked AstraZeneca’s VP of Strategic Partnering & Business Development. Are you curious to find out more about what pharma companies look for in a licensing partner? Shaun Grady...

Articles
Adherence - the bridge between clinical and real world outcomes

Adherence - the bridge between clinical and real world outco...

Adherence is not just a problem to be addressed once a drug has launched, but a pivotal factor in determining outcomes, which makes it a key part of the value proposition for market access. Whilst the term ‘market access’ is well used within pharma, it does mean different things to different people. Historically, it has focussed on the payer alone and negotiating…

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D